Glenmede Trust’s bluebird bio BLUE Stock Holding History

Glenmede Trust’s Portfolio BLUE Stock Details BLUE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q1	–	Sell	-1,000	Closed	-$27.6K	–	1349
2023 Q4	$27.6K	Buy	+1,000	New	+$61K	﹤0.01%	1244
2020 Q4	–	Sell	-25	Closed	-$17K	–	1340
2020 Q3	$17K	Buy	25 +9	+56%	+$7.02K	﹤0.01%	1668
2020 Q2	$12K	Buy	16 +12	+300%	+$9.05K	﹤0.01%	1790
2020 Q1	$4K	Hold	4	–	–	﹤0.01%	2705
2019 Q4	$4K	Hold	4	–	–	﹤0.01%	2705
2019 Q3	$4	Hold	4	–	–	﹤0.01%	2686
2019 Q2	$6	Hold	4	–	–	﹤0.01%	2553
2019 Q1	$8	Hold	4	–	–	﹤0.01%	2435
2018 Q4	$5	Buy	+4	New	+$6.14K	﹤0.01%	2523
2016 Q3	–	Sell	-12	Closed	-$5K	–	2581
2016 Q2	$5K	Sell	12 -8	-40%	-$4.53K	﹤0.01%	2234
2016 Q1	$11K	Buy	+20	New	+$12.3K	﹤0.01%	2013
2015 Q3	–	Hold	0	–	–	–	2716
2015 Q2	–	Hold	0	–	–	–	2686
2015 Q1	–	Hold	0	–	–	–	2450

Other funds holding BLUE

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

GIM

Granahan Investment Management Waltham, Massachusetts $2.07B AUM 56.45% 1-Year Est. Return

Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

PAI

Palo Alto Investors Palo Alto, California $654M AUM 77.8% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return

TCM

Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return

Glenmede Trust's BLUE Position: Q1 2024 in Review

Glenmede Trust sold out of bluebird bio (BLUE) in Q1 2024, closing a stake of 1,000 shares — an estimated $27.6K sold.

Glenmede Trust first reported a position in BLUE in Q1 2016 and held it in 11 quarters. The position peaked at $27.6K in Q4 2023. 158 funds tracked by Wall St. Rank hold BLUE as of Q1 2024.

Glenmede Trust reported no remaining bluebird bio position as of Q1 2024 after selling out during the quarter.
Glenmede Trust sold 1,000 bluebird bio shares in Q1 2024, an estimated $27.6K.
Glenmede Trust first reported a position in bluebird bio in Q1 2016 and held it in 11 quarters.
Glenmede Trust's bluebird bio position peaked at $27.6K in Q4 2023.
158 funds tracked by Wall St. Rank held bluebird bio as of Q1 2024.

Based on Glenmede Trust's 13F filing for Q1 2024, filed 15 May 2024.